Clinical Domain Certificate

Metabolism and Weight Management

Incretin biology, metabolic syndrome and emerging metabolic therapies

A focused certificate exploring obesity, metabolic syndrome, insulin resistance, incretin biology and emerging metabolic therapies through current scientific evidence and clinical reasoning.

Coming soonDates to be announcedPricing to be announced

About this programme

Each Clinical Domain Certificate examines a specific area of clinical practice through current scientific evidence, biological mechanisms and structured clinical reasoning. The certificate begins with a dedicated introductory gateway module before progressing into domain-specific content.

Learning objectives

Describe the physiology of energy balance and weight regulation.
Interpret current evidence for incretin-based therapies.
Appraise published trials of emerging metabolic agents.
Apply governance principles when discussing non-authorised compounds.
Communicate metabolic risk and treatment uncertainty to patients.

Programme outline

Energy balance and the biology of obesity
Insulin resistance and the metabolic syndrome
Incretin biology (GLP-1, GIP) and downstream signalling
Authorised and emerging metabolic therapies — critical appraisal
Cardiometabolic risk assessment
Long-term safety, governance and patient selection

Format

Online modular learning, gateway module plus domain content, structured assessment.

Audience

Qualified healthcare practitioners working in or adjacent to metabolic medicine.

Prerequisites

Completion of Introduction to Peptides in Health and Disease, or equivalent.

Dates & pricing

Enrolment dates, fees and admissions criteria will be published in due course. To register interest, please use the enquiry form on the home page.

This programme is educational in nature and written for a United States audience. It does not promote, market or recommend any drug, biologic, device or dietary supplement, and it does not provide prescribing protocols. The U.S. regulatory status of individual peptides — including approval, investigational status, and eligibility for pharmacy compounding under Sections 503A/503B — is determined by the FDA and may change over time. Clinical decisions remain the responsibility of individual U.S.-licensed practitioners operating within their state scope of practice and applicable federal and state law. See our full regulatory disclaimer.

← PreviousFoundation programmeIntroduction to Peptides in Health and Disease Next →Clinical Domain CertificateMuscle Health and Healthy Ageing